Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
Launched by MASONIC CANCER CENTER, UNIVERSITY OF MINNESOTA · May 8, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of managing pain after a surgery called pancreatoduodenectomy, which involves removing part or all of the pancreas and the duodenum (the first part of the small intestine). The trial compares a technique called rectus sheath block, where a long-lasting pain medication called liposomal bupivacaine is injected into the abdomen to help control pain, with a traditional method known as thoracic epidural analgesia (TEA), which uses a catheter placed in the spine to deliver pain relief medication.
To join this study, participants must be adults aged 18 and older who are having this specific surgery at the University of Minnesota. However, individuals with certain conditions that may complicate the procedure, such as bleeding disorders or allergies to local anesthetics, as well as those who have been using high doses of opioids before the surgery, may not be eligible. If you participate, you can expect to receive one of the two pain management methods and will be monitored for how well it helps control your pain after surgery. This trial aims to see if the new approach is just as effective as the traditional one while possibly offering fewer side effects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients, age 18 and older, undergoing open pancreaticoduodenectomy at the University of Minnesota will be included in the study
- Exclusion Criteria:
- • Patients with contraindication to block placement (coagulopathy, local anesthetic allergy, infection)
- • Patients with chronic opioid use (at least 30 milligram morphine equivalents \[MME\] for 3 or more weeks leading up to surgery)
- • Patients unable to understand the quality of recovery survey intellectual barriers. This will be determined by the primary investigator/attending anesthesiologist's discretion
- • Patient refusal and those who have opted out of research
- • Pregnant patients - will be assessed through review of the medical record
About Masonic Cancer Center, University Of Minnesota
The Masonic Cancer Center at the University of Minnesota is a leading institution dedicated to cancer research, treatment, and prevention. As a National Cancer Institute-designated Comprehensive Cancer Center, it integrates innovative research with clinical practice to enhance patient care and advance medical knowledge. The center fosters collaboration among scientists, clinicians, and educators, focusing on multidisciplinary approaches to tackle the complexities of cancer. Through its commitment to cutting-edge clinical trials, the Masonic Cancer Center aims to translate scientific discoveries into effective therapies, ultimately improving outcomes for cancer patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
James Flaherty
Principal Investigator
University of Minnesota Masonic Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported